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Contents  
During the last decade, analysis of anti-Müllerian hormone (AMH), highly conserved 
between mammalian species, has contributed to new information in reproductive 
endocrinology, due to clinically available diagnostic assays. AMH is produced solely in 
the gonads; in the Sertoli cells of testes and granulosa cells of the ovary, and thus offers 
possibilities to diagnose physiologic and pathologic conditions involving these organs. 
This paper reviews indications for AMH analysis in cats and dogs, include diagnosing 
presence of gonads, and granulosa or Sertoli cell tumors. Diagnostic challenges are 
addressed. One specific organ, the prostate, is commonly affected by pathologic changes in 
older dogs. A commercial assay for analyzing canine prostatic specific esterase (CPSE) 
enables analysis of CPSE in clinical practice, of potential value of in the work-up of 
benign prostatic hyperplasia in male dogs. This is described in this review, as is a new 
method for analysis of steroids: liquid chromatography-tandem mass spectrometry LC-
MS/MS. Steroids have since long been analyzed in studies on reproduction, and LC-
MS/MS has the advantage of allowing analysis of panels of multiple steroids from small 
sample volumes. Altogether, these available methods may give new insights into small 
animal reproduction, and are valuable tools for the practicing veterinarian. 
 
Keywords: AMH, castration, BPH, LC-MS/MS 
 
Introduction 
The development of small animal reproduction is dependent on suitable tools for studies of 
physiological and pathological phenomena. Recently, commercial immunoassays have 
become available for analysis of anti-Müllerian hormone (AMH) and canine prostate 
specific esterase (CPSE). These methods allows studies of gonadal function and of the 
prostate, respectively, and may thus contribute to new insights that can be valuable for the 
clinician working within the field of reproduction (Holst and Dreimanis 2015; Levy et al. 
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2014; Place et al. 2011; Themmen et al. 2016; Turna Yilmaz et al. 2015). Traditionally, 
steroid analysis using immunoassays have dominated reproductive endocrinology. With a 
new method; liquid chromatography and tandem mass spectrometry (LC-MS/MS), 
analysis of panels of steroid hormones is possible. This enables a more complete picture of 
ongoing events within small animal reproduction (Holst et al. 2015). 
 
Anti-Müllerian hormone (AMH) 
Anti-Müllerian hormone (AMH), also called Müllerian inhibiting substance (MIS), is a 
glycoprotein that belongs to the transforming growth factor (TGF) β family (Josso and di 
Clemente 1999). The use of AMH analyses in human reproductive endocrinology has 
increased over the last decade, mainly for assessing the ovarian reserve (Brodin et al. 
2013; Nelson and La Marca 2011).  
AMH is found exclusively in gonadal somatic cells; Sertoli cells in males and granulosa 
cells in females (Josso and di Clemente 1999). An important biological role, and the 
reason for the name of the hormone, is the triggering of the regression of fetal Müllerian 
ducts in males (Josso et al. 2013). The immature Sertoli cell produces high concentrations 
of AMH, and strong expression has been described in Sertoli cells of fetal canine testicles 
(Banco et al. 2012). After puberty, testosterone inhibits AMH production through the 
androgen receptor, that is expressed by mature Sertoli cells (Josso et al. 2013), Figure 1. 
AMH also inhibits the activity of Leydig cells (Racine et al. 1998). 
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Figure 1. (Please see caption at the end of this document.) 
 
In females, AMH is expressed mainly in pre-antral and small antral follicles, in dogs as in 
other species (Nagashima et al. 2016). AMH has been shown to inhibit initiation of 
primordial follicle growth (Durlinger et al. 2002), thus protecting the ovary from a 
premature exhaustion of the follicle pool. In addition, AMH has been shown to inhibit the 
stimulatory effect of FSH on growth of preantral and small antral follicles (Durlinger et al. 
2001), an effect that is important during cyclic recruitment.  
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Figure 2. (Please see caption at the end of this document.) 
 
Clinical implications of AMH in male dogs and cats (summarized in Table 1, end of 
this document.) 
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Cryptorchidism or castration 
AMH is a reliable test for diagnosing castration status in male cats (Axner and Strom Holst 
2015). AMH concentrations are high in adult males, and even higher before puberty 
(Axner and Strom Holst 2015; Josso et al. 2013). Analysis of AMH can thus be used for 
detection of testicles irrespective of age of the male. In dogs, calves and hoses, analysis of 
AMH was predictive of testicular tissue, irrespective if it was abdominal or not (Claes et 
al. 2013; Gharagozlou et al. 2014; Kitahara et al. 2012a). Analysis of AMH is not suitable 
for evaluation of chemical castration (e.g. with deslorelin), as this has been seen to result 
in increased concentrations of AMH in dogs (above the highest standard point, 
unpublished personal observation). 
 
Presence of Sertoli cell tumors 
AMH has been described to be a useful marker for immature and neoplastic canine Sertoli 
cells (Banco et al. 2012). Dogs with testicular tumors of Sertoli cell origin had a ten to 
thousand times higher serum concentration than healthy dogs or dogs with other testicular 
pathologies (Ano et al. 2014; Holst and Dreimanis 2015). In the diagnostic workup of 
testicular tumors, other tests may also be helpful, such as preputial cytology when estrogen 
production is suspected (Dreimanis et al. 2012).  
 
Infertility investigations 
Important functions are attributed to the Sertoli cell, including a sustentacular and nutritive 
role for germ cells, organization of spermiation, production of endocrine and paracrine 
substances that regulate spermatogenesis, secretion of androgen binding protein, and 
interaction with the Leydig cells (Holstein et al 2003). Because the serum AMH 
concentration reflects Sertoli cell function, it may constitute an additional diagnostic 
parameter in male subfertility (Iliadou et al. 2015). In men, the concentration of AMH in 
seminal plasma, but not in serum, was shown to be associated with sperm count and 
motility (Andersen et al. 2016). At present, there are no published studies on the 
relationship between AMH and fertility in male cats or dogs. 
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Clinical implications of AMH in female dogs and cats 
Presence of ovaries or ovarian remnants 
The analysis of AMH can distinguish ovariohysterectomized from intact cats and dogs 
(Place et al. 2011). In a recent study, 27/30 (90%) of intact and all 29 spayed bitches 
bitches were correctly identified (Themmen et al. 2016). This can be compared to 
measurement of luteinizing hormone (LH) in serum, that correctly identified 78% of intact 
and 98% of ovariectomized bitchese (n = 300) (Lofstedt and Vanleeuwen 2002). In cats, 
analysis of AMH has been described as a reliable test for differentiating spayed from intact 
females, correctly identifying all 16 intact and 15 spayed females (Axner and Strom Holst 
2015). Using LH, all 16 intact and 14/15 (n = 94%) of the spayed cats were correctly 
diagnosed (Rohlertz et al. 2012). 
AMH has been used for diagnosing ovarian remnants in cats (Place et al. 2011) and dogs 
(Turna Yilmaz et al. 2015). Significantly lower mean serum concentrations of AMH were 
detected in spayed bitches (0.28 ± 0.09 ng/ml) than in intact bitches (4.26 ± 0.82 ng/ml) or 
bitches with ovarian remnants (4.4 ± 1.09 ng/ml), using the AMH enzyme linked 
immunosorbent assay (ELISA) from Ansh Labs (Webster, USA) (Turna Yilmaz et al. 
2015).  
An effect of age has not been reported for dogs or cats, but in humans, concentrations of 
AMH decrease with age independent of number of pregnancies (La Marca et al. 2012), and 
concentrations below the detection limit have been shown both in ovariectomized and 
postmenopausal women (La Marca et al. 2005).  
 
Presence of granulosa cell tumors 
AMH is a specific marker for granulosa cell tumors (GCT) in women (La Marca and 
Volpe 2007), mares (Ball et al. 2013) and cows (El-Sheikh Ali et al. 2013; Kitahara et al. 
2012b), with high concentrations in females with GCTs. There are no published reports of 
this use in cats or dogs, but in our lab we have analyzed high concentrations of AMH 
(above the highest standard point) in two bitches with confirmed GCTs. 
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Infertility investigations  
In humans, elevated AMH concentrations are useful for diagnosing the polycystic ovarian 
syndrome, a common cause of anovulatory infertility (Jamil et al. 2016). Obese patients 
with reduced fertility due to reduced ovarian reserve and dysfunctional folliculogenesis 
have low concentrations of AMH (Jamil et al. 2016). AMH concentrations vary between 
intact individuals, but concentrations of AMH are considered relatively independent of 
cycle stage in cows (Monniaux et al. 2012) and women (van Disseldorp et al. 2010). 
There is a large inter-individual variation in both dogs and cats (Axner and Strom Holst 
2015; Nagashima et al. 2016; Place et al. 2011), with an unknown relationship to fertility. 
The use of AMH analysis in infertility investigations has not been evaluated for these 
species. 
 
In vitro fertilization techniques and determination of the ovarian reserve 
The concentration of AMH reflects the antral follicle count (AFC) in cattle (Ireland et al. 
2011) and women. Analysis of AMH concentrations has been useful for predicting 
follicular and ovulatory response to gonadotrophin treatment for embryo transfer in cows 
(Rico et al. 2012), and is also predictive for embryo production in the goat (Monniaux et 
al. 2011). It is a widely used tool in human IVF settings (Brodin et al. 2013). In bitches, an 
AMH peak has been described preceding the LH peak, coinciding with the rise and fall in 
the number of early antral follicles (Nagashima et al. 2016). The rise in AMH has therefore 
been suggested to enable prediction of onset of estrus, and monitoring AMH may enable 
prediction of ovulation ten days in advance. This may improve collection of pre-ovulatory 
oocytes for IVF. The correlation between AMH and the AFC is of potential value in 
endangered canine populations, e.g. for planning of best breeding pairs and population 
planning with aging individuals (Nagashima et al. 2016). 
 
AMH in disorders of sexual differentiation (DSD) 
Analysis of AMH can be used clinically when investigating disorders of sex development 
in humans (Josso et al. 2013; Lindhardt Johansen et al. 2013). For example, men with the 
Klinefelter syndrome (47, XXY) have subnormal AMH concentrations after puberty that 
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may be explained by a progressive destruction of testicular tissue (Aksglaede et al. 2011). 
In virilized females, AMH concentrations within the male reference range is seen in cases 
with testicular tissue, whereas AMH concentrations within the female reference range can 
be seen in cases with a high production of adrenal androgens (Josso et al. 2013; Lindhardt 
Johansen et al. 2013). Several DSDs have been reported in dogs and cats (Meyers-Wallen 
2012), but there are as yet no reports on the use of AMH analysis in DSD investigations in 
these species. 
 
Interpretation of AMH test results with different immunoassays 
Initially, two commercial ELISAs available for human samples, one from Diagnostic 
Systems Lab (DSL) and one from Immunotech (IOT) (Nelson and La Marca 2011), were 
widely used also for other species. They were followed by a third assay, AMH Gen II 
(Beckman coulter). AMH Gen II assay was calibrated against the IOT, and values 
achieved are in the same range (Kumar et al. 2010). Compared with the DSL assay, one 
report found values to be approximately 40% higher with the AMH Gen II assay (Wallace 
et al. 2011), while another study instead reported values that were approximately 20% 
lower (Rustamov et al. 2012). Account must be taken to these differences when 
interpreting results using the different assays. One factor that may influence the results is 
the storage time, which has been reported to result in increasing values when whole blood 
(~30% after 3.5 days) or serum (~30% after 2 days) was stored at room temperature 
(Fleming et al. 2013; Rustamov et al. 2012). This increase during storage may be due to a 
dissociation of the AMH molecule (Rustamov et al. 2012). Another potential cause is 
interference by complement (Weber et al. 1990). Since 2013, a pre-mixing step is 
introduced for the AMH Gen II assay, increasing reproducibility of measurements (Han et 
al. 2014). Recently, the same antibodies as used in the AMH Gen II assay have been used 
in two fully automated immunoassays, with higher analytical sensitivity (van Helden and 
Weiskirchen 2015). Studies on dogs or cats have not been published using the automated 
methods. Commercial ELISAs developed for use in dogs have recently become available 
and used (Turna Yilmaz et al. 2015). In Table 1, the different ELISAs that have been used 
for cats and dogs are shown. 
In the study by Place and co-workers, using the DSL assay, one spayed bitch was 
considered having a falsely high AMH concentration, being a statistical outlier (Place et al. 
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2011). In our laboratory, we have had single cases of high concentrations of AMH in 
neutered males/spayed female dogs. This may be due to remnant gonadal tissue. It may 
also be caused by assay interference; presence of heterophilic antibodies has been reported 
to cause falsely high concentrations of AMH in humans (Cappy et al. 2013). Except for 
this single bitch, all spayed bitches had AMH concentrations below the lowest standard 
point (Place et al. 2011). However, several intact bitches, especially bitches < 6 months of 
age, had non-detectable AMH concentrations, leading to overlapping results (Place et al. 
2011). This overlap is a potential problem when assessing presence of gonads in dogs. The 
degree of overlap may vary depending on which assay is used. In the study by Turna 
Yilmaz et al (Turna Yilmaz et al. 2015), all prepubertal bitches had measurable 
concentrations. 
In cats, one study reported all spayed females and neutered males to have non-detectable 
concentrations, whereas all intact cats had measurable concentrations, and there was thus 
no overlap (Axner and Strom Holst 2015). Higher concentrations in cats than in dogs have 
been reported previously (Place et al. 2011), reducing the difficulty of interpretation of the 
results due to overlap, and the problem with overlap seems to be less. 
The concentration reported for intact bitches in the study by Turna Yilmaz et al 
(4.26 ± 0.82 ng/ml) (Turna Yilmaz et al. 2015) and Themmen et al (3.9 ±2.7 ng/ml) 
(Themmen et al. 2016), both using the Ansh ELISA, are high compared to other studies: 
range 0.1-0.41 ng/ml (Place et al. 2011), using the DSL ELISA, and 0.3 ± 0.01 ng/ml to 
0.64 ± 0.03 ng/ml during proestrus (Nagashima et al. 2016), using the AMH Gen II 
ELISA. It is important that each laboratory establishes own reference intervals for their 
test. The importance of developing an international standard for AMH has been stressed in 
human medicine (Li et al. 2012), and is certainly needed also in veterinary medicine. 
Values reported as ng/ml (pg/l) can be converted to SI units: 1 ng/ml = 7.14 pM.  
Table 1.  
 
Another new diagnostic possibility: Canine prostate specific esterase (CPSE)  
A commercial ELISA has become available for the analysis of canine prostate specific 
esterase (CPSE). CPSE is an arginine esterase and the major secretory product of the 
canine prostate (Chapdelaine et al. 1984). CPSE is regulated by testosterone (Juniewicz et 
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al. 1990). Serum CPSE activity has been described to be significantly higher in dogs with 
BPH than in normal dogs (Bell et al. 1995; Wolf et al. 2012), but did not differ between 
dogs with BPH, bacterial prostatitis and prostatic carcinoma (Bell et al. 1995). CPSE is 
thus a potentially valuable biomarker for prostatic enlargement, and can be included in the 
diagnostic workup of dogs with clinical signs of BPH and for screening of geriatric dogs 
(Levy et al. 2014).  
 
New possibilities with liquid chromatography tandem mass spectrometry (LC-
MS/MS) 
An increasing number of human clinical pathology laboratories are offering liquid 
chromatography tandem mass spectrometry, LC-MS/MS, for analyses of steroid hormones 
(Field 2013; Stanczyk and Clarke 2010). The method is often replacing immunoassays for 
these hormones because of better specificity and sensitivity and the high reproducibility 
(Shackleton 2010). LC-MS/MS has been used for the simultaneous quantitation of 
multiple steroids in several species (Koren et al. 2012). One great advantage is the 
possibility to quantify panels of steroid hormones and patterns of steroid hormone 
metabolites (Stanczyk and Clarke 2010). In addition, LC-MS/MS allows quantitation of 
hormones for which no immunoassays are commercially available, e.g. pregnanes (Holst et 
al. 2015). The amount of serum needed is small, and the technique is valuable when the 
sample volume is limited, such as in small breeds or young animals. The method has been 
used to study steroid profiles in dogs with X-linked muscular dystrophy (Martins-Junior et 
al. 2015) and to study steroid profiles in pregnant dogs (Holst et al. 2015). The method is 
not common in veterinary clinical pathology laboratories and the availability for routine 
diagnostics within veterinary medicine is thus limited, but it is a promising method for the 
future. 
 
Conclusion 
Analysis of AMH, a hormone specific for the mammalian gonads, enables new 
possibilities for diagnosing presence of gonads and gonadal tumors. The value of AMH in 
infertility investigations and IVF settings remains to be investigated. A new methodology, 
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LC-MS/MS, enables analysis of panels of steroids. Analysis of CPSE can be helpful in 
diagnostic workups of geriatric dogs. 
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Table 1. Use of AMH in clinical studies in dogs and cats 
 
Species Indication Test kit No of animals Reference 
Dog Presence of ovaries in 
females 
DSL/Ansh 
Labs 
112 (2 ovarian 
remnants)/94 
(Place et al. 
2011)/(Themmen 
et al. 2016) 
Dog Presence of ovarian 
remnants 
Ansh Labs 46 (Turna Yilmaz et 
al. 2015) 
Dog Presence of testes in 
males 
AMH Gen 
II/ AMH 
Gen II/Ansh 
Labs 
24/5/98 (Gharagozlou et 
al. 2014)/(Ano et 
al. 
2014)/(Themmen 
et al. 2016) 
Dog Presence of Sertoli cell 
tumors 
AMH Gen II 47/5 (Holst and 
Dreimanis 
2015)/(Ano et al. 
2014) 
Dog Study the transition 
from anestrus to estrus 
AMH Gen II 5 (Nagashima et 
al. 2016) 
Cat Presence of gonads in 
females and males 
AMH Gen II 31 + 27/32 (Axner and 
Strom Holst 
2015)/(Place et 
al. 2011) 
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Captions: 
Figure 1. 
Testosterone inhibits AMH production through the androgen receptor, that is expressed by 
mature Sertoli cells (Josso et al. 2013). AMH reduces the testosterone production via an 
AMH receptor on the Leydig cells (Racine et al. 1998). FSH has a stimulatory effect on 
AMH expression that is evident the absence of androgens, like in the immature testis 
(Josso et al. 2001). The information on the function of AMH in males is from experiments 
carried out in laboratory animals, mostly mice and rats. FSH: follicle stimulating hormone, 
FSH-R: FSH- receptor, AMH: anti-Müllerian hormone, AR: androgen receptor, LH: 
luteinizing hormone, LH-R: LH- receptor. 
 
Figure 2. 
AMH is produced mainly in pre-antral and small antral follicles, that has been shown in 
several species, including dogs (Nagashima et al. 2016). In mice, it has been shown that 
AMH inhibits initiation of primordial cell growth, probably due to a direct effect of AMH 
on the primordial follicle, and FSH-stimulated follicle growth, by decreasing the 
sensitivity of growing follicles to AMH (Durlinger et al. 2002; Durlinger et al. 2001). 
AMH may thus play a role in the determination of follicles to undergo selection or atresia 
(Visser and Themmen 2005). Green arrows: stimulatory function of FSH. Red arrows: 
inhibitory effect of AMH. Brown: Oocyte. Blue: Granulosa cells. Yellow: antrum. 
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